Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer's Disease(AD)

Next Previous
Trial Profile

Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer's Disease(AD)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APH 1105 (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aphios Corporation

Most Recent Events

  • 26 Jul 2021 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
  • 26 Jul 2021 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2024.
  • 26 Jul 2021 Planned initiation date changed from 1 Jun 2021 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top